{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:42:16Z","timestamp":1792755736440,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00259-014-2713-y","type":"journal-article","created":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T06:04:42Z","timestamp":1393481082000},"page":"1280-1292","source":"Crossref","is-referenced-by-count":334,"title":["Radiation dosimetry and first therapy results with a 124I\/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy"],"prefix":"10.1007","volume":"41","author":[{"given":"Christian M.","family":"Zechmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Armor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Mier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Joyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Babich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"2713_CR1","unstructured":"American Cancer Society, Inc., Surveillance Research; Cancer Facts & Figures, 2012."},{"key":"2713_CR2","unstructured":"National Cancer Institute, Surveillance Epidemiology and End Results. SEER stat fact sheets: prostate. Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"2713_CR3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-5347(01)62921-5","volume":"160","author":"MS Litwin","year":"1998","unstructured":"Litwin MS et al. Epidemiological trends and financial outcomes in radical prostatectomy among medicare beneficiaries, 1991 to 1993. J Urol. 1998;160:445\u20138.","journal-title":"J Urol"},{"key":"2713_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"J Ahmedin","year":"2011","unstructured":"Ahmedin J et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"2713_CR5","first-page":"5237","volume":"60","author":"PM Smith-Jones","year":"2000","unstructured":"Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237.","journal-title":"Cancer Res"},{"key":"2713_CR6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339.","journal-title":"J Cell Biochem"},{"key":"2713_CR7","doi-asserted-by":"crossref","first-page":"7195s","DOI":"10.1158\/1078-0432.CCR-1004-0023","volume":"11","author":"S Vallabhajosula","year":"2005","unstructured":"Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11:7195s.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2713_CR8","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","volume":"22","author":"MI Milowsky","year":"2004","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522\u201331.","journal-title":"J Clin Oncol"},{"key":"2713_CR9","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, et al. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591\u2013601.","journal-title":"J Clin Oncol"},{"key":"2713_CR10","first-page":"850","volume":"46","author":"A Vallabhajosula","year":"2005","unstructured":"Vallabhajosula A, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850\u20138.","journal-title":"J Nucl Med"},{"key":"2713_CR11","doi-asserted-by":"crossref","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA)monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Can Res 2013. Aug 26 Epub ahead of print.","DOI":"10.1158\/1078-0432.CCR-13-0231"},{"issue":"2","key":"2713_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm800994j","volume":"52","author":"KP Maresca","year":"2009","unstructured":"Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52(2):347\u201357.","journal-title":"J Med Chem"},{"key":"2713_CR13","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","volume":"69","author":"SM Hillier","year":"2009","unstructured":"Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932\u201340.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"2713_CR14","first-page":"170","volume":"53","author":"S Hillier","year":"2012","unstructured":"Hillier S, Rubino K, Maresca K, Marquis J, Tesson M, Zimmerman C, et al. [131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa). J Nucl Med. 2012;53 Suppl 1:170.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"2713_CR15","first-page":"361","volume":"52","author":"S Hillier","year":"2011","unstructured":"Hillier S, Merkin R, Maresca K, Zimmerman C, Barrett J, Tesson M, et al. [131I]MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa). J Nucl Med. 2011;52 Suppl 1:361.","journal-title":"J Nucl Med"},{"key":"2713_CR16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","volume":"53","author":"A Levitzki","year":"2013","unstructured":"Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013;53:161\u201385.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2713_CR17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-Complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem. 2012;23:688\u201397.","journal-title":"Bioconjugate Chem"},{"key":"2713_CR18","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"issue":"3","key":"2713_CR19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2967\/jnumed.112.111203","volume":"54","author":"JA Barrett","year":"2013","unstructured":"Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of two high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54(3):380\u20137.","journal-title":"J Nucl Med"},{"key":"2713_CR20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ijc.2910620511","volume":"62","author":"JK Troyer","year":"1995","unstructured":"Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552\u20138.","journal-title":"Int J Cancer"},{"key":"2713_CR21","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"2713_CR22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50:472\u201383.","journal-title":"Histopathology"},{"key":"2713_CR23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2012.523","volume":"108","author":"L Bourke","year":"2013","unstructured":"Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer. 2013;108:9\u201313.","journal-title":"Br J Cancer"},{"key":"2713_CR25","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-12-3779","volume":"19","author":"AA Veldt van der","year":"2013","unstructured":"van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [11C]docetaxel and positron emission tomography. Clin Cancer Res. 2013;19:4163\u201373.","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-014-2713-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2713-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T21:21:46Z","timestamp":1565212906000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-014-2713-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["2713"],"URL":"https:\/\/doi.org\/10.1007\/s00259-014-2713-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}